EMA validates application of Genmab-Pfizer cervical cancer treatment
2024-02-05
临床结果临床3期临床2期抗体药物偶联物快速通道
Preview
来源: Pharmaceutical Technology
Genmab-Pfizer’s cervical cancer treatment is under EMA review. Credit: Jo Panuwat D / Shutterstock.com.
The European Medicines Agency (EMA) has validated the marketing authorisation application (MAA) for review of Genmab and Pfizer’s tisotumab vedotin to treat recurrent or metastatic cervical cancer.
The antibody-drug conjugate (ADC) would become the first treatment option in the European Union for adult cervical cancer patients whose disease has advanced on or following systemic therapy.
The MAA submission is based on results from the randomised, international Phase III innovaTV 301 trial.
The trial enrolled 502 patients who had received no more than two systemic regimens previously for recurrent or metastatic cervical cancer.
See Also:Regeneron’s linvoseltamab application accepted for review
Preview
来源: Pharmaceutical Technology
Biosyngen’s liver cancer therapy receives fast track designation
Preview
来源: Pharmaceutical Technology
The findings are compared to those obtained from chemotherapy treatments.
The primary goal of the study was to assess overall survival, while secondary outcomes included progression-free survival and quality-of-life measures.
Data from the innovaTV 204 Phase II single-arm trial of tisotumab vedotin monotherapy was also included in the application.
The safety profile observed in the innovaTV 301 trial aligns with the known safety information provided in the US prescribing details.
Genmab CEO Jan van de Winkel stated: “The validation of our application is an important milestone supporting our commitment to bringing a new therapeutic option for recurring or metastatic cervical cancer to more patients.
“There continues to be a need for therapeutic options for these patients, and we’re dedicated to delivering potentially improved outcomes to women diagnosed with this devastating disease.”
Tisotumab vedotin combines Genmab’s human monoclonal antibody targeting tissue factor with the ADC technology of Pfizer.
Pfizer Oncology chief development officer Roger Dansey stated: “The milestone signifies our progress in exploring the availability of tisotumab vedotin for more patients with recurrent or metastatic cervical cancer.
“We remain dedicated to collaborating closely with regulatory authorities, while we navigate the process to potentially deliver a new therapeutic option to people facing this debilitating disease.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。